Photo from wikipedia
To synthesise available data regarding the disease‐free survival (DFS) benefit of adjuvant immune checkpoint inhibitors (ICIs) for patients with renal cell carcinoma (RCC) and evaluate the overall safety profile of… Click to show full abstract
To synthesise available data regarding the disease‐free survival (DFS) benefit of adjuvant immune checkpoint inhibitors (ICIs) for patients with renal cell carcinoma (RCC) and evaluate the overall safety profile of ICIs in this setting.
Keywords:
adjuvant immunotherapy;
cell carcinoma;
renal cell;
immunotherapy renal;
carcinoma systematic
Journal Title: BJU International
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: BJU International
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!